From: Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer
Group | No | ANXA2 | ANXA4 | ||
---|---|---|---|---|---|
Mean histoscore [95Â % CI] | P value | Mean histoscore (95Â % CI) | P value | ||
 Normal | 46 | 133 [111–156] | 0.002 | 34 [21–46] | <0.001 |
 Cancer | 336 | 94 [88–101] |  | 73 [65–81] |  |
Age | Â | Â | Â | Â | Â |
 <50 year | 203 | 95 [87–103] | 0.731 | 79 [68–89] | 0.096 |
 >50 year | 133 | 93 [83–103] |  | 65 [53–77] |  |
FIGO Stage | Â | Â | Â | Â | Â |
 ≤ IIA | 291 | 90 [83–97] | 0.002 | 74 [66–83] | 0.543 |
 ≥ IIB | 45 | 121 [103–138] |  | 67 [47–88] |  |
Cell type | Â | Â | Â | Â | Â |
 SCC | 256 | 101 [93–108] | <0.001 | 51 [44–58] | <0.001 |
 AD/ASC | 80 | 73 [62–84] |  | 145 [126–163] |  |
Tumor size | Â | Â | Â | Â | Â |
 ≤4 cm | 256 | 90 [82–97] | 0.010 | 76 [66–85] | 0.317 |
 >4 cm | 80 | 109 [96–121] |  | 66 [49–83] |  |
LVSI | Â | Â | Â | Â | Â |
 Negative | 202 | 88 [80–96] | 0.019 | 83 [72–93] | 0.005 |
 Positive | 133 | 104 [93–114] |  | 60 [48–72] |  |
Depth of invasion | Â | Â | Â | Â | Â |
 <50 % | 108 | 70 [60–80] | <0.001 | 70 [55–84] | 0.565 |
 ≥50 % | 228 | 106 [98–113] |  | 75 [65–85] |  |
LN metastasis | Â | Â | Â | Â | Â |
 Negative | 256 | 88 [81–95] | 0.002 | 76 [66–85] | 0.250 |
 Positive | 80 | 113 [100–127] |  | 65 [50–81] |  |
PM involvement | Â | Â | Â | Â | Â |
 Negative | 305 | 92 [85–98] | 0.031 | 74 [65–82] | 0.662 |
 Positive | 31 | 118 [95–141] |  | 68 [42–94] |  |
Resection margin | Â | Â | Â | Â | Â |
 Negative | 323 | 94 [87–100] | 0.420 | 75 [66–83] | 0.032 |
 Positive | 13 | 111 [66–157] |  | 43 [15–71] |  |
Primary Treatment | Â | Â | Â | Â | Â |
 OP only | 171 | 82 [73–90] | <0.001 | 78 [66–90] | 0.354 |
 OP + RT | 70 | 110 [95–125] |  | 71 [53–89] |  |
 OP + CCRT | 90 | 107 [95–119] |  | 68 [54–82] |  |
 Neoadjuvant | 5 | 75 [45–105] |  | 26 [8–59] |  |